Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

BACKGROUND: Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor α. AIM: In the first randomised plac...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Brooklyn, T N, Dunnill, M G S, Shetty, A, Bowden, J J, Williams, J D L, Griffiths, C E M, Forbes, A, Greenwood, R, Probert, C S
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2006
Témata:
Inflammatory Bowel Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856164/
https://ncbi.nlm.nih.gov/pubmed/16188920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.074815
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky